Quick and easy sterile connections for single-use biopharmaceutical processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Quick and easy sterile connections for single-use biopharmaceutical processing

AseptiQuik® connectors from CPC make single-use sterile connections faster, easier and safer than ever before.Robust, easy-to-use connector designs enable users to quickly transfer valuable media with more confidence and less risk of operator error. AseptiQuik® connectors provide reliable, sterile connections without the need for clamps, fixtures or tube welding.

The newest addition to CPC’s sterile connection technologies, genderless AseptiQuik® G connectors simplify single-use systems design and process integration. Our innovative design eliminates separate male and female components to substantially reduce complexity and support modular system design. Because the connectors are interchangeable—any single-use G series connector mates with any other G series connector—systems are more flexible and minimize supply chain complexity.

The AseptiQuik family offers the broadest range of single-use sterile connectors in the industry with flow configurations from 3.2mm to 25.4mm (1/8” to 1”). AseptiQuik’s are ideal for applications where reliability and sterility are a must—including single-use bag and tubing assemblies, cell banking systems, bioreactors, mixers, sampling, formulation and filling. See the AseptiQuikvideos.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here